ODD spin-out receives over £2 million to take its drug discovery programme to the next level
Oxford Drug Design wins UK-China AMR grant and boosts funding with investment from the
Oxford Drug Design Limited (ODD), a biotechnology company with a
proprietary computational and machine learning platform, has raised a combined £2.2M in funding
from the Angel CoFund (ACF), o2h Ventures and other new investors, and grant funding from the UK
Department of Health and Social Care (DHSC)'s UK-China research competition. This brings the
firm's total amount of grant and equity funding raised in 2019 to over £9M.